Board ReviewInternal medicineStudy guide

GI Cancers by Organ for the Medicine Shelf: Risk Factors, Classic Stems and First Tests

Esophageal, gastric, pancreatic, liver, biliary and colorectal cancer in one table, plus the workup for painless jaundice and iron deficiency anemia.

Step 2 CK outlineGastrointestinal SystemDiagnosisLaboratory/Diagnostic StudiesMixed ManagementMedicineSurgery

A microscope beside a tray of stained tissue slides
AI-generated image
Contents
  1. GI cancers at a glance
  2. The approach to painless jaundice
  3. The work-up of iron deficiency anemia in an older adult
  4. Treatment pearls the shelf still asks
  5. Clue in the stem, next best step
  6. Where students lose points
  7. Practice question
  8. 60-second recall
  9. Sources

On the medicine shelf, a GI cancer question usually hands you a risk factor and one physical finding (a smoker with painless jaundice, a man with iron deficiency anemia, a patient with cirrhosis and a new liver nodule) and asks for the first test. The cancer is rarely in doubt. The order of tests is what gets scored.

GI cancers at a glance

CancerBiggest risk factorsClassic stemFirst diagnostic testPearl
Esophageal adenocarcinomaChronic GERD, Barrett esophagus, obesity, smokingOlder man, progressive dysphagia to solids then liquids, weight lossUpper endoscopy with biopsyDistal third of the esophagus
Esophageal squamous cell carcinomaSmoking, heavy alcohol use, achalasia, caustic injurySame dysphagia pattern, upper or middle esophagusUpper endoscopy with biopsyThe most common type worldwide
Gastric adenocarcinomaH. pylori, smoked and salted foods, smoking, germline CDH1 (diffuse type)Early satiety, weight loss, left supraclavicular node, periumbilical noduleUpper endoscopy with biopsyDiffuse type: signet ring cells, linitis plastica
Pancreatic adenocarcinomaSmoking, chronic pancreatitis, obesity, diabetes, family history, BRCA variantsPainless jaundice, weight loss, palpable nontender gallbladder, migratory thrombophlebitisPancreatic-protocol (multiphase) CTCA 19-9 tracks the disease; it does not make the diagnosis
Hepatocellular carcinomaCirrhosis from any cause, hepatitis B even without cirrhosis, hepatitis C, alcohol, MASLDPatient with cirrhosis who decompensates, or a new nodule on surveillance ultrasoundMultiphase CT or MRIArterial enhancement with washout is diagnostic without biopsy
CholangiocarcinomaPrimary sclerosing cholangitis, liver flukes, choledochal cystPainless jaundice with a hilar stricture, often in a patient with ulcerative colitisMRI with MRCPERCP with brushings gives tissue and drainage
Gallbladder carcinomaGallstones, porcelain gallbladder, large polyps, PSCFound at cholecystectomy, or RUQ pain with weight lossUltrasound, then CTIn PSC, a gallbladder polyp larger than 8 mm goes to cholecystectomy
Colorectal adenocarcinomaAge, adenomas, inflammatory bowel disease, Lynch syndrome, FAPRight side: iron deficiency anemia. Left side: hematochezia, narrow stools, obstructionColonoscopy with biopsyStreptococcus gallolyticus bacteremia calls for a colonoscopy

The approach to painless jaundice

Painless jaundice in an older adult is cancer until proven otherwise. The sequence below is what the shelf rewards.

  1. Confirm a cholestatic patternRaised direct bilirubin and alkaline phosphatase out of proportion to the aminotransferases.
  2. Right upper quadrant ultrasoundLook for dilated bile ducts and stones. Dilated ducts without stones point to a distal obstruction.
  3. Pancreatic-protocol CT for a distal obstructionMultiphase CT shows the mass, its relation to the mesenteric vessels and any liver metastases, which decides resectability.
  4. No mass on CT but high suspicion: endoscopic ultrasoundEUS finds small tumors that CT misses and allows fine-needle biopsy when tissue is needed.
  5. Hilar stricture: MRI with MRCP, then ERCPMRCP maps the ducts; ERCP adds brushings for cytology and a stent for drainage. This is the cholangiocarcinoma path.
  6. Use CA 19-9 lastIt supports the picture and tracks treatment response, but benign biliary obstruction also raises it.

The work-up of iron deficiency anemia in an older adult

In a man or a postmenopausal woman, iron deficiency anemia means GI blood loss until proven otherwise. The 2020 AGA guideline sets the steps.

  1. Confirm iron deficiencyAGA uses a ferritin cutoff of 45 ng/mL to diagnose iron deficiency.
  2. Bidirectional endoscopyUpper endoscopy and colonoscopy for asymptomatic men and postmenopausal women with iron deficiency anemia.
  3. Celiac serology before duodenal biopsyIn asymptomatic adults, AGA suggests noninvasive celiac testing first and biopsy only if it is positive.
  4. Test for H. pylori and treat if positiveNoninvasive testing is suggested as part of the evaluation.

Never accept diet or a low-grade cause as the explanation in this group without endoscopy. A right-sided colon cancer often presents with anemia and nothing else.

Treatment pearls the shelf still asks

  • Advanced hepatocellular carcinoma: first-line systemic therapy is atezolizumab plus bevacizumab or durvalumab plus tremelimumab (AASLD 2023). Sorafenib is no longer the first-line answer.
  • Small HCC within transplant criteria in decompensated cirrhosis: liver transplant evaluation. Resection is for patients with preserved liver function.
  • Resectable pancreatic cancer: surgery with adjuvant chemotherapy (modified FOLFIRINOX for fit patients), or neoadjuvant therapy first. Offer germline genetic testing to every patient.
  • Low-grade gastric MALT lymphoma with H. pylori: eradication therapy first.
  • Colorectal cancer after resection: CEA is for surveillance, not for screening.

Clue in the stem, next best step

Clue in the stemWhat it points toNext best step
70-year-old man, hemoglobin 9.8 g/dL, ferritin 6 ng/mL, no GI symptomsIron deficiency anemia from occult GI lossUpper endoscopy and colonoscopy
Painless jaundice, palpable nontender gallbladder, dilated ducts without stonesPeriampullary or pancreatic head massPancreatic-protocol CT
CT negative, persistent obstruction and weight lossSmall pancreatic tumorEndoscopic ultrasound
Recurrent superficial venous clots in different veins, weight lossTrousseau syndromeLook for an occult cancer, pancreatic first
Cirrhosis, new 2.5 cm nodule on ultrasoundPossible HCCMultiphase CT or MRI
Streptococcus gallolyticus endocarditisColonic neoplasmColonoscopy
Ulcerative colitis, cholestatic labs, hilar strictureCholangiocarcinoma in PSCMRCP, then ERCP with brushings
Early satiety, weight loss, hard left supraclavicular nodeGastric cancerUpper endoscopy with biopsy

Where students lose points

  • Ordering CA 19-9, CEA or AFP to diagnose a cancer. Markers support imaging and track treatment; they do not replace a diagnostic test.
  • Choosing ERCP as the first test for painless jaundice. Imaging comes first; ERCP is for tissue, brushings or drainage.
  • Stopping at colonoscopy for iron deficiency anemia. Both the upper and lower GI tract are examined.
  • Biopsying a liver nodule that already meets imaging criteria for HCC.
  • Assuming no cirrhosis means no HCC risk. Hepatitis B can cause HCC in a noncirrhotic liver.
  • Listing sorafenib as first-line therapy for advanced HCC. Immunotherapy combinations replaced it.

Practice question

A 67-year-old man comes to the physician because of yellow skin and dark urine for 2 weeks. He has lost 6 kg over 3 months without trying. He has no abdominal pain or fever. He has smoked 1 pack of cigarettes daily for 40 years and was diagnosed with type 2 diabetes 6 months ago. Temperature is 37.0 C. He is jaundiced. A nontender, distended gallbladder is palpable in the right upper quadrant. Total bilirubin is 9.2 mg/dL (direct 7.8 mg/dL), alkaline phosphatase 610 U/L, AST 88 U/L and ALT 102 U/L. Ultrasound shows dilated intrahepatic and extrahepatic bile ducts and a dilated pancreatic duct, with no gallstones.

Which of the following is the most appropriate next step in diagnosis?

  1. Serum CA 19-9
  2. Hepatobiliary iminodiacetic acid scan
  3. Multiphase pancreatic-protocol CT of the abdomen
  4. ERCP with biliary stent placement
  5. Laparoscopic cholecystectomy
Show the answer

Answer: C. Painless jaundice, weight loss, new diabetes and a palpable nontender gallbladder with a dilated bile duct and pancreatic duct (the double duct sign) point to a pancreatic head cancer. Multiphase CT confirms the mass and stages it, including vascular involvement, which decides whether it can be resected.

Why the others are wrong. A: CA 19-9 supports the diagnosis and is used for monitoring, but obstructive jaundice alone can raise it. B: a HIDA scan evaluates acute cholecystitis, not a painless obstruction. D: ERCP is for drainage or tissue once imaging defines the lesion; routine preoperative stenting is not the first step. E: the gallbladder is distended because of a distal obstruction, not gallbladder disease.

60-second recall

Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.

  1. 1First test for dysphagia with weight loss
    Upper endoscopy with biopsy.
    Did you get it?
  2. 2First test for painless jaundice with dilated ducts and no stones
    Pancreatic-protocol CT.
    Did you get it?
  3. 3CT negative but high suspicion for pancreatic cancer
    Endoscopic ultrasound.
    Did you get it?
  4. 4HCC on imaging
    Arterial enhancement plus washout; no biopsy needed.
    Did you get it?
  5. 5Iron deficiency anemia in an older adult
    Ferritin under 45 ng/mL, then EGD and colonoscopy.
    Did you get it?
  6. 6Advanced HCC first-line
    Atezolizumab plus bevacizumab, or durvalumab plus tremelimumab.
    Did you get it?

Next: browse every Board Review post, review the GI cancer progression pathways, or see MedRise for students.

Sources

  1. Ko CW, et al. AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia. Gastroenterology, 2020 (PubMed 32810434)
  2. Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. JAMA, 2021 (PubMed 34547082)
  3. Singal AG, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 2023 (PubMed 37199193)
  4. Bowlus CL, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2023 (PubMed 36083140)
  5. Shaheen NJ, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol, 2022 (PubMed 35354777)
  6. Chey WD, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol, 2024 (PubMed 39626064)
  7. US Preventive Services Task Force. Colorectal cancer: screening. Final recommendation statement, 2021

MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.

Learned something the hard way on a shelf or on the wards?

Write it up for MedRise Perspectives: 600 to 1,200 words, published under your name, with a decision usually within one day.

Book a free strategy call

Ten minutes to look at your exam date, your scores and what is getting in the way.